Heron Therapeutics announces U.S. commercial launch of APONVIE

Heron Therapeutics announced APONVIE (aprepitant) injectable emulsion, is now commercially available for intravenous use in adults for the prevention of PONV. Delivered via a single IV injection, APONVIE reaches drug levels associated with greater than or equal to97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours. This ready-to-use, easy to administer, innovative IV formulation ensures rapid and consistent exposure in patients undergoing surgery. Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to the current standard-of-care, IV ondansetron.